In Vivo



Drug efficacy assay


In most cases, we evaluate the efficacy of your compounds against the growth of patient-derived tumor xenografts implanted subcutaneously into nude mice.









Among XenTech’s PDX models, several have been described to be spontaneously metastatic.
XenTech is developing innovative solutions to track metastases spread, explore the biology of metastases development and to evaluate anti-metastatic therapies.


Bioluminescent tumor PDX models : Several of our PDX are being engineered to express high levels of luciferase, allowing longitudinal monitoring and quantification of tumor cells by in vivo real time bioluminescence imaging (Xenogen IVIS® Lumina imaging system).














Residual disease


Some of XenTech’s PDX models (breast, colorectal, lung and glioma) have been qualified for investigating chemoresistant residual disease.


These models allow developing novel therapeutic agents directed against tumor cells responsible for relapses in solid malignancies.










Custom-made tumor models


In addition to PDX subcutaneous implantation, we can develop upon request :


–  Tumor cell line-based xenograft models.

–  Orthotopic models, using either our own PDX collection or any commercially available tumor cell line.

Orthotopically-growing tumors growth is monitored over time using ultrasound system (Vevo 770, Visuasonics®).